Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | ERN1 | O75460 | 9/20 | 0.63 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.52 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30933727 | 0.77 | ERN1 (1.00) | GAAKDM4EALDH1A1ERN1MAPT | |
| SCHEMBL455724 | 0.77 | ERN1 (1.00) | GAAKDM4EALDH1A1ERN1MAPT | |
| SCHEMBL2697239 | 0.77 | ERN1 (0.57) | GAAKDM4EALDH1A1ERN1MAPT | |
| SCHEMBL1541991 | 0.75 | ERN1 (0.64) | GAAKDM4EALDH1A1ERN1ALOX5 | |
| SCHEMBL8264537 | 0.75 | GAA (0.61) | GAAKDM4EALDH1A1ERN1PTK6 | |
| SCHEMBL13944216 | 0.74 | ERN1 (0.51) | GAAKDM4EALDH1A1ERN1PTK6 | |
| SCHEMBL14976694 | 0.74 | MEN1 (0.62) | KDM4EALDH1A1ERN1MAPTKMT2A | |
| SCHEMBL23652104 | 0.73 | ERN1 (0.53) | GAAKDM4EALDH1A1ERN1PTK6 | |
| SCHEMBL2317614 | 0.72 | CA12 (0.68) | GAAKDM4EALDH1A1ERN1MAPT | |
| SCHEMBL2559703 | 0.72 | ERN1 (0.71) | GAAKDM4EALDH1A1ERN1PTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189306-A1 | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES | KARTNER NORBERT | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189306-A1 | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES | ATP6V1E1, ATP6V1G1, ATP6V1H | GAA 7/4885KDM4E 2907/4885ALDH1A1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.